^
    Apply
    Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) (NCT03829319)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/21/2025
    Initiation :
    03/25/2019
    Primary completion :
    08/11/2023
    Completion :
    08/30/2024
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed
    Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors (NCT04669496)
    Phase 2/3
    Shanghai Zhongshan Hospital
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/20/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    TMB • MSI • CEACAM5 • MUC16
    |
    PD-L1 expression
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin
    A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) (NCT04819100)
    Phase 3
    Eli Lilly and Company
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/20/2021
    Primary completion :
    05/01/2027
    Completion :
    08/01/2032
    RET
    |
    RET fusion
    |
    Retevmo (selpercatinib)
    Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) (NCT03829332)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    03/13/2019
    Primary completion :
    05/19/2021
    Completion :
    04/24/2024
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities ((MARGARET)) (NCT04683250)
    Phase 1/2
    Taiho Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/16/2020
    Primary completion :
    03/01/2030
    Completion :
    03/01/2031
    RET
    |
    RET fusion
    |
    vepafestinib (TAS0953/HM06)
    Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) (LITESPARK-016) (NCT04976634)
    Phase 2
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    08/18/2021
    Primary completion :
    03/22/2027
    Completion :
    03/22/2027
    MSI
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)
    Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma (NCT05532059)
    Phase 2
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/31/2022
    Primary completion :
    08/31/2025
    Completion :
    08/31/2028
    PD-L1
    |
    cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma (NCT05823311)
    Phase 3
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    09/01/2023
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    PD-L1
    |
    cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-321) (NCT04280081)
    Phase 2
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    03/16/2020
    Primary completion :
    03/25/2021
    Completion :
    11/01/2027
    RET
    |
    RET mutation
    |
    Retevmo (selpercatinib)
    A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET Lung) (NCT04222972)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    07/24/2020
    Primary completion :
    01/27/2025
    Completion :
    01/27/2025
    RET
    |
    RET fusion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)
    Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (NCT04662710)
    Phase 3
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/30/2020
    Primary completion :
    10/29/2024
    Completion :
    03/31/2026
    PD-L1
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • Lenvima (lenvatinib) • capecitabine • oxaliplatin • leucovorin calcium • levoleucovorin calcium
    Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer (NCT04759911)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    02/26/2021
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    RET
    |
    Retevmo (selpercatinib)